Skip to main content

Table 5 Descriptive data of acute myeloid leukemia patients (group III)

From: Telomerase reverse transcriptase gene amplification in hematological malignancies

Parameter

AML patients (N = 15)

Age (mean ± SD)

47.2 ± 7.5

Gender, N (%)

 Male

9 (60%)

 Female

6 (40%)

Presentation, N (%)

 DNV

11 (73.3%)

 Relapse

4 (26.7%)

Lymphadenopathy, N (%)

8 (53.3%)

Splenomegaly, N (%)

4 (26.7%)

Hepatomegaly, N (%)

3 (20%)

WBC count (× 109/l) (mean ± SD)

8.8 ± 5.9

Hb level (g/dl) (mean ± SD)

11.3 ± 2.4

Platelet count (× 109/l) (mean ± SD)

110 ± 38

BM blasts % (mean ± SD)

68 ± 21

Karyotype, N (%)

 Normal

8 (53.3%)

 Numerical aberrations

4 (26.7%)

 Structural aberrations

3 (20%)

TERT amplification, N (%)

8 (53.3%)

Prognosis, N (%)

 Good

8 (53.3%)

 Intermediate

3 (20.1%)

 Bad

4 (26.6%)

  1. BM bone marrow, DNV de novo, Hb hemoglobin, TERT telomerase reverse transcriptase, WBCs white blood cells